Peptide directory

Find a peptide

Public profiles inside a larger governed registry

Search by peptide name, brand, or research code. Open a full evidence profile or the published sources available for a record still in development. Source publication does not mean a completed scientific appraisal.

The registry is an expanding catalog, not a complete list of every peptide. A missing public result does not mean no research exists.

There are 51 full evidence profiles. "Complete profiles" is a stricter subset of them (12): Full profiles that pass every blocking completion check (published sources, a documented review of a source, chemistry, two regulatory records, linked conclusions and the narrative sections). A full evidence profile that is not yet complete has simply not passed every one of those checks.

Published profiles

Search profiles and sources

Compare peptides side by side →
Refine by category
Category

14 peptide records (14 full evidence profiles, 0 source-only records)

  • Growth-hormone fragment analog

    AOD-9604

    Developing

    AOD-9604 is a modified peptide derived from the C-terminal region of human growth hormone and was developed to investigate lipolytic and anti-obesity effects while attempting to avoid the broader growth-promoting actions of full-length growth hormone.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 4Preclinical 11Durable IDs 23Open signals 4
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    22 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Synthetic research peptide

    BPC-157

    Developing

    BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence associated with gastric proteins. Experimental studies report effects on angiogenesis, nitric-oxide signaling, inflammatory pathways, and tissue repair, but the proposed mechanisms are not established as therapeutic mechanisms in humans.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 4Preclinical 16Durable IDs 26Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    23 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Long-acting GHRH analog

    CJC-1295

    Developing

    CJC-1295 is a modified growth-hormone-releasing hormone analog designed to resist enzymatic degradation and, in its drug-affinity-complex form, bind circulating albumin. Early studies show prolonged stimulation of growth hormone and IGF-1, but biomarker elevation is not equivalent to demonstrated clinical benefit.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 2Preclinical 21Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Synthetic tetrapeptide bioregulator

    Epitalon

    Emerging

    Epitalon (also transliterated Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly associated with Russian peptide-bioregulator research. Proposed effects include modulation of gene expression, circadian biology, oxidative stress, and telomerase-related pathways, but mechanisms and clinical relevance remain uncertain.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 1Preclinical 14Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    22 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Endogenous copper-binding peptide complex

    GHK-Cu

    Peptide conjugate

    Emerging

    GHK-Cu is the copper(II) complex of the endogenous tripeptide glycyl-L-histidyl-L-lysine. It binds copper and has been studied in copper handling, extracellular-matrix remodeling, fibroblast activity, inflammatory signaling, antioxidant responses, and wound repair. Effects are formulation-, concentration-, route-, and model-dependent.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 8Durable IDs 24Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    No published regulatory entry on file
    Research questions
    22 open research questions
    Evidence review date
    Documented human review recorded Sep 8, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth-hormone secretagogue

    Ipamorelin

    Developing

    Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue that activates the ghrelin receptor (GHSR1a). It was designed to stimulate pulsatile growth-hormone release with less ACTH or cortisol stimulation than some earlier secretagogues.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 3Preclinical 14Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Alpha-MSH-derived tripeptide

    KPV

    Emerging

    KPV is the C-terminal tripeptide Lys-Pro-Val of alpha-melanocyte-stimulating hormone. Preclinical studies associate KPV and related analogs with anti-inflammatory and antimicrobial effects, including modulation of NF-kB-linked signaling and epithelial inflammatory responses.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 0Preclinical 19Durable IDs 30Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    24 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Mitochondrial-derived peptide

    MOTS-c

    Developing

    MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Experimental work links it to cellular stress responses, AMPK-related metabolism, nuclear signaling, exercise adaptation, and age-associated physiology.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 4Preclinical 14Durable IDs 29Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    20 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • GIP/GLP-1/glucagon receptor agonist

    Retatrutide

    Peptide analog

    Developing

    Retatrutide (LY3437943) is an investigational long-acting peptide engineered to activate GIP, GLP-1, and glucagon receptors. Published early-phase and phase 2 studies report glycemic, body-weight, and liver-fat effects, but retatrutide has no FDA-approved indication. Gray-market products are not validated by these studies.

    • 25 published sources
    • 25 with study appraisals
    • 26 linked conclusions
    • Complete profile
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 7Preclinical 0Durable IDs 27Open signals 2
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    21 open research questions
    Evidence review date
    Documented human review recorded Sep 8, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • GLP-1 receptor agonist

    Semaglutide

    Peptide analog

    Substantial

    Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1) engineered for resistance to DPP-4 degradation and prolonged albumin binding. It selectively activates the GLP-1 receptor. In humans, its pharmacologic effects include glucose-dependent stimulation of insulin secretion, reduced glucagon secretion, delayed gastric emptying, reduced calorie intake, and lower body weight. Clinical effects and approved uses depend on the formulation, indication, population, and regulatory jurisdiction; this archive separates those contexts rather than treating semaglutide as a single undifferentiated claim.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 22Preclinical 1Durable IDs 25Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    25 open research questions
    Evidence review date
    Documented human review recorded Sep 22, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • Synthetic thymosin-related research peptide

    TB-500

    Developing

    TB-500 is a non-standardized market name commonly associated with a synthetic fragment or derivative of thymosin beta-4. Thymosin beta-4 binds actin and has been studied in cell migration, angiogenesis, inflammation, and repair; those findings cannot automatically be attributed to every product sold as TB-500.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 3Preclinical 17Durable IDs 28Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    25 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • Growth hormone-releasing hormone analog

    Tesamorelin

    Peptide analog

    Developing

    Tesamorelin is a stabilized N-terminally modified analog of the 44-amino-acid human growth hormone–releasing hormone. It activates pituitary GHRH receptors, increasing endogenous growth-hormone release and downstream IGF-1 signaling. In the labeled population this pathway reduces visceral adipose tissue; it is not a general weight-loss mechanism.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 16Preclinical 0Durable IDs 28Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    1 published regulatory entry
    Research questions
    24 open research questions
    Evidence review date
    Documented human review recorded Sep 8, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

  • Immune-modulating thymic peptide

    Thymosin alpha-1

    Substantial

    Thymosin alpha-1 (thymalfasin) is an N-terminally acetylated 28-amino-acid peptide originally isolated from thymic tissue and corresponding to a region of prothymosin alpha. It has context-dependent immunomodulatory effects involving dendritic-cell maturation, innate pattern-recognition signaling, T-cell function, cytokine regulation, and restoration of immune responsiveness; these mechanisms do not imply benefit for every immune or infectious condition.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    Evidence and record details

    Evidence integrity map

    Human 18Preclinical 2Durable IDs 26Open signals 3
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    23 open research questions
    Evidence review date
    No documented human review recorded

    Source verification checks records; it does not itself approve scientific conclusions.

  • GIP/GLP-1 receptor agonist

    Tirzepatide

    Peptide analog

    Substantial

    Tirzepatide is a long-acting peptide agonist at GIP and GLP-1 receptors. Controlled programs evaluate glycemic control, chronic weight management, withdrawal, obesity-related obstructive sleep apnea, HFpEF with obesity, and MASH. Regulatory conclusions remain indication- and label-specific.

    • 25 published sources
    • 25 with study appraisals
    • 25 linked conclusions
    • Complete profile
    • Documented human review
    Evidence and record details

    Evidence integrity map

    Human 15Preclinical 0Durable IDs 27Open signals 2
    Publication state
    Published profile
    Verified source records
    25 source records verified
    Chemistry record
    Chemistry record on file
    Regulatory entries
    2 published regulatory entries
    Research questions
    20 open research questions
    Evidence review date
    Documented human review recorded Sep 8, 2026

    Source verification checks records; it does not itself approve scientific conclusions.

How the public directory relates to the 501-record Master Registry

master registry transparency

501 master records, with governance status shown explicitly

WPF-MASTER-REGISTRY-TRANSPARENCY-1.0
501
Master records
467
Governed records
34
Review-deferred
458
Eligible for literature search
9
Governed comparators

The master registry has 467 governed identities from 501 records. 34 remain review-gated. Nine governed records are scientific comparators, leaving 458 peptide identities in the literature-search cohort (identities whose published literature WPF searches for; it does not refer to obtaining or buying any product). Database reconciliation is a separate step. The 51 profiles shown on this directory are a represented public-profile subset, not the size of the master registry. All 51 public profiles on this render reconcile to governed peptide identities in that registry; unknown, duplicate, deferred, or comparator identities fail closed instead of appearing publicly.

Which number counts what

  • 501 master records: the known registry of peptide and comparator identities (a catalog, never assumed complete).
  • 405 directory records in the search above: 51 full evidence profiles plus 354 source-only records (identities with published, verified sources but no full profile). The 23 result pages hold 18 records each and are counted from this same list.
  • 51 full evidence profiles: the profiles in the JSON export and the structured data on this page.
  • The observation form’s peptide selector uses a separate, more permissive list of identities that can be reported on; it is not the directory and not the evidence corpus.
Explore the full Master Registry →
What the profile status labels mean

Evidence, chemistry, and regulatory counts include only records that crossed the relevant public-publication gate. A zero means none published in that lane—not that nothing is known. “No governed record published” is a publication-state disclosure; internal or pending material may exist without appearing in public counts. Source verification, editorial publication, and accountable scientific appraisal are distinct states; a source count alone does not approve a scientific conclusion.

Recently updated public records

When each public profile record was last changed — not clinical or scientific activity.

Peptide Directory — World Peptide Foundation